In this study, we aimed to identify the associations between individual mutations in KRAS, STK11, KEAP1, or TP53, as well as the comutation status of these genes, and the TMB with clinical outcomes of patients with lung adenocarcinoma treated with immune checkpoint inhibitors (ICIs). Here, KRAS is linked to lung adenocarcinoma.